CD8A and myeloid sarcoma: Overall, more samples in the aCD20-MS group [CD4+,17/19 (89.5%); CD8+, 17/19 (89.5%)] were above the positivity threshold compared to the healthy control group [CD4+, 10/17 (58.8%); CD8+, 7/17 (41.2%)].